Equity Research
Company-level stock analysis, valuation, margins, balance sheet risk, and rating rationale.
Research Desk

Company-level stock analysis, valuation, margins, balance sheet risk, and rating rationale.
Post-publication reviews that check what happened after earlier Buy and Sell calls.
Daily filing-change notes comparing new 10-K language with prior-year disclosures.
Friday performance updates for the public LF0 research track record.
Smith & Wesson Brands (SWBI) 2026 10-K analysis comparing the 17 June 2026 filing with its prior-year 10-K, highlighting the MD&A section’s biggest changes.
A ranked snapshot of 10-K language changes for companies that filed annual reports on 16 June 2026.
Vistagen Therapeutics (VTGN)’s Business section changed the most among 7 companies that filed 10-Ks on 15 June 2026, each compared against its prior-year filing.
A ranked snapshot of 10-K language changes for companies that filed annual reports on 12 June 2026.
A ranked snapshot of 10-K language changes for companies that filed annual reports on 11 June 2026.
Subscribe
Equity research, scorecards, weekly performance updates, and SEC filing-change summaries.